Bone Is a Target for the Antidiabetic Compound Rosiglitazone

Rosiglitazone is an FDA-approved oral antidiabetic agent for the treatment of type 2 diabetes. This compound improves insulin sensitivity through the activation of the nuclear receptor, peroxisome proliferator-activated receptor-γ (PPAR-γ). In addition to sensitizing cells to insulin, the PPAR-γ2 is...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: RZONCA, S. O., SUVA, L. J., GADDY, D., MONTAGUE, D. C., LECKA-CZERNIK, B.
Format: Artigo
Sprog:Inglês
Udgivet: 2003
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC1855213/
https://ncbi.nlm.nih.gov/pubmed/14500573
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/en.2003-0746
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker